NCT02135523View on ClinicalTrials.gov

The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 6, 2014

Primary Completion Date

January 8, 2018

Study Completion Date

January 8, 2018

Conditions
Ovarian Cancer (Epithelial)
Interventions
RADIATION

involved-field radiation therapy

Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.

Trial Locations (1)

120-752

Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02135523 - The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial | Biotech Hunter | Biotech Hunter